Presentations

Egetis – Corporate Presentation November 2023

November 8, 2023

Egetis – Corporate Presentation October 2023

October 23, 2023

Egetis – Corporate Presentation August 2023

August 30, 2023

Egetis – Corporate Presentation July 2023

July 7, 2023

Egetis Presentation – Investor and Analyst Webinar 29 June 2023

June 29, 2023

Egetis – Corporate Presentation June 2023

May 30, 2023

Egetis – Corporate Presentation May 2023

May 16, 2023

Egetis Corporate Presentation February 2023

February 23, 2023

Egetis Corporate Presentation January 2023

January 17, 2023

Egetis Corporate Presentation December 2022

December 20, 2022

Egetis Corporate Presentation November 2022

November 28, 2022

Redeye interview with CEO Nicklas Westerholm

November 24, 2022

Egetis Corporate Presentation October 2022

October 18, 2022

Egetis Corporate Presentation September 2022

September 28, 2022

Egetis – Corporate Presentation August 2022

August 22, 2022

Redeye interview with CEO after Q2 report

August 19, 2022

Pareto interview with Peder Walberg and Nicklas Westerholm 

July 25, 2022

Nicklas Westerholm presenting at ABGSC Life Science Summit

May 18, 2022

Egetis – Corporate Presentation May 2022

May 17, 2022

Peder Walberg presenting at Redeye Orphan Drugs event

April 27, 2022

Handelsbanken Healthy Hour

March 23, 2022

Redeye interview with CEO after Q4 report 17 February 2022

February 17, 2022

Webcast regarding US regulatory path

January 18, 2022

Webcast regarding marketing authorisation application for Emcitate®

December 13, 2021

Redeye life science day

November 11, 2021

Redeye interview with the CEO in connection with the Q3 report

November 4, 2021

Interview with Peder Walberg at Pareto, operative director of the board and founder of Rare Thyroid Therapeutics (in Swedish)

October 28, 2021

Presentation at Penser

30 september, 2021

The Pareto Healthcare conference presentation

September 1, 2021

ABGSC Life Science Summit

May 25

Erik Penser Bank – Commercialization of pharmaceuticals

May 6, 2021

Aktiedagen (in Swedish)

May 4

Redeye Orphan Drugs

April 28, 2021

Interview with Dr Thomas Lönngren, nominated CoB and CEO Nicklas Westerholm

April 1, 2021

Interview with CEO Nicklas Westerholm at Redeye

February 18, 2021

Interview with CEO Nicklas Westerholm in Pareto TV

February 1, 2021

Company investor and analyst presentation – acquisition of RTT

October 5, 2020

Acquisition of Rare Thyroid Therapeutics – Interview at Redeye

October 5, 2020

Egetis and RTT agree to join forces

October 5, 2020

Pareto Healthcare Seminar – Company presentation

September 2, 2020